Arch Venture Corp
Latest statistics and disclosures from ARCH Venture Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Parabilis Medicines, BEAM, RAPP, Seaport Therapeutics, ERAS, and represent 68.45% of ARCH Venture Management's stock portfolio.
- Added to shares of these 3 stocks: Parabilis Medicines (+$176M), Seaport Therapeutics (+$137M), BOLD (+$6.7M).
- Started 3 new stock positions in Parabilis Medicines, BOLD, Seaport Therapeutics.
- Reduced shares in these 2 stocks: VIR, QTTB.
- Sold out of its position in QTTB.
- ARCH Venture Management was a net buyer of stock by $315M.
- ARCH Venture Management has $1.1B in assets under management (AUM), dropping by 62.50%.
- Central Index Key (CIK): 0001274403
Tip: Access up to 7 years of quarterly data
Positions held by Arch Venture Corp consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for ARCH Venture Management
ARCH Venture Management holds 12 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Parabilis Medicines | 16.0 | $176M | NEW | 6.4M | 27.37 |
|
| Beam Therapeutics (BEAM) | 14.2 | $156M | 4.5M | 34.31 |
|
|
| Rapport Therapeutics (RAPP) | 14.1 | $155M | 3.7M | 41.67 |
|
|
| Seaport Therapeutics Common Stock | 12.4 | $137M | NEW | 6.3M | 21.70 |
|
| Erasca (ERAS) | 11.8 | $130M | 7.1M | 18.32 |
|
|
| Vir Biotechnology (VIR) | 11.8 | $129M | 13M | 10.19 |
|
|
| Maze Therapeatics (MAZE) | 11.2 | $123M | 4.1M | 29.85 |
|
|
| Lyell Immunopharma Com New (LYEL) | 4.1 | $46M | 3.2M | 14.02 |
|
|
| Generate Biomedicines Com Shs (GENB) | 3.0 | $33M | 1.9M | 16.87 |
|
|
| 10x Genomics Cl A Com (TXG) | 0.8 | $8.4M | 218k | 38.34 |
|
|
| Boundless Bio (BOLD) | 0.6 | $6.7M | NEW | 2.7M | 2.50 |
|
| Gossamer Bio (GOSS) | 0.1 | $1.3M | 8.1M | 0.16 |
|
Past Filings by ARCH Venture Management
SEC 13F filings are viewable for ARCH Venture Management going back to 2018
- ARCH Venture Management 2026 Q2 filed Aug. 14, 2026
- ARCH Venture Management 2026 Q1 filed May 15, 2026
- ARCH Venture Management 2025 Q4 filed Feb. 17, 2026
- ARCH Venture Management 2025 Q3 filed Nov. 14, 2025
- ARCH Venture Management 2025 Q2 filed Aug. 14, 2025
- ARCH Venture Management 2025 Q1 filed May 15, 2025
- ARCH Venture Management 2024 Q4 filed Feb. 14, 2025
- ARCH Venture Management 2024 Q3 filed Nov. 14, 2024
- ARCH Venture Management 2024 Q2 filed Aug. 14, 2024
- ARCH Venture Management 2024 Q1 filed May 15, 2024
- ARCH Venture Management 2023 Q4 filed Feb. 14, 2024
- ARCH Venture Management 2023 Q3 filed Nov. 14, 2023
- ARCH Venture Management 2023 Q2 filed Aug. 9, 2023
- ARCH Venture Management 2023 Q1 filed May 15, 2023
- ARCH Venture Management 2022 Q4 filed Feb. 14, 2023
- ARCH Venture Management 2022 Q3 filed Nov. 10, 2022